Optiscan Imaging
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 1 Dec 2025
- Reported shorts
- 12.5K
- Shares on issue
- 1.044B
Optiscan Imaging (OIL) Short Interest
Optiscan Imaging (ASX:OIL) had 0.00% of shares reported as short positions as of 1 Dec 2025, representing 12,500 shares. Optiscan Imaging operates in the Health Care Equipment & Services industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Optiscan Imaging
Optiscan Imaging Ltd. focuses on the research and development of advanced medical imaging technologies. Their primary focus is on a High Magnification Endoscope for clinical diagnosis and research, alongside continued sales of their research-grade benchtop confocal microscope system within Australia.
Company profile →Optiscan Imaging (ASX:OIL) has 0.00% of its shares on issue reported as short positions as of 1 Dec 2025, or about 12,500 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.23% in September 2010. OIL is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads OIL today
- Zanger BreakoutWatchScore 6rank 1920 of 1942
- CAN SLIMWatchScore 15rank 867 of 1541
- Minervini Trend TemplateWatchScore 59rank 195 of 1716
- Crowded-Short BreakoutWatchScore 9rank 1171 of 1500
- Quality compoundersWatchScore 30rank 432 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
OIL fundamentals
In the year to 30 Jun 2026, Optiscan Imaging (ASX:OIL) recorded revenue of A$448.8K and a net loss after tax of A$7.0M. A year earlier it recorded revenue of A$951.9K and a net loss after tax of A$6.3M. Year-on-year growth: revenue −52.9% (FY). Net margin −1,556.7%, return on equity −52.4% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest OIL news
All news- Optiscan Imaging Moves Closer to Regulatory Clearance of Real-Time Surgical Imaging Platform
smallcaps · 5 Oct 2026
- Long Shortz with Optiscan: InVue reaches major US FDA milestone
stockhead · 4 Oct 2026
- Optiscan’s InVue surgery imaging tech heads to US FDA
stockhead · 4 Oct 2026
Company details
More Health Care Equipment & Services Stocks
Other shorted stocks in this sector
Be the first to discuss OIL
Start a research thread or post the first pulse update